Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
COYA Quote, Financials, Valuation and Earnings
Last price:
$4.83
Seasonality move
:
29.02%
Day range:
$4.61 - $4.87
52-week range:
$3.94 - $8.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.34x
P/B ratio:
3.72x
Volume:
83.2K
Avg. volume:
259K
1-year change:
-26.29%
Market cap:
$101.5M
Revenue:
$3.6M
EPS (TTM):
-$1.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
COYA
Coya Therapeutics, Inc.
|
$1.9M | -$0.30 | -20.12% | -19.15% | $16.07 |
|
ABBV
AbbVie, Inc.
|
$16.4B | $2.65 | 10.4% | 319.23% | $246.63 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
AVIR
Atea Pharmaceuticals, Inc.
|
-- | -$0.49 | -- | -31.71% | $7.67 |
|
ELMD
Electromed, Inc.
|
$18M | -- | 11.79% | -- | $36.67 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.93% | 134.73% | $1,202.37 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
COYA
Coya Therapeutics, Inc.
|
$4.85 | $16.07 | $101.5M | -- | $0.00 | 0% | 20.34x |
|
ABBV
AbbVie, Inc.
|
$228.72 | $246.63 | $404.2B | 96.62x | $1.73 | 2.91% | 6.63x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.20 | $31.21 | $3.9B | 14.93x | $0.00 | 0% | 3.73x |
|
AVIR
Atea Pharmaceuticals, Inc.
|
$4.60 | $7.67 | $359.4M | -- | $0.00 | 0% | 0.84x |
|
ELMD
Electromed, Inc.
|
$24.81 | $36.67 | $205.3M | 24.15x | $0.00 | 0% | 3.16x |
|
LLY
Eli Lilly & Co.
|
$1,020.56 | $1,202.37 | $962.8B | 45.18x | $1.73 | 0.61% | 14.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
COYA
Coya Therapeutics, Inc.
|
-- | -0.492 | -- | 7.67x |
|
ABBV
AbbVie, Inc.
|
104% | -0.239 | -- | 0.47x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
AVIR
Atea Pharmaceuticals, Inc.
|
0.33% | 0.572 | 0.46% | 16.32x |
|
ELMD
Electromed, Inc.
|
-- | 0.920 | -- | 4.40x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.536 | 4.56% | 0.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
COYA
Coya Therapeutics, Inc.
|
$3.6M | -$1.9M | -57.41% | -57.41% | -53.78% | -$1.6M |
|
ABBV
AbbVie, Inc.
|
$14B | $5.8B | 6.03% | 144.3% | 34.96% | $6.6B |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
AVIR
Atea Pharmaceuticals, Inc.
|
-$104K | -$45.6M | -36.83% | -36.97% | -- | -$40.4M |
|
ELMD
Electromed, Inc.
|
$14.8M | $3.6M | 20.33% | 20.35% | 19.16% | $2.4M |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
Coya Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns COYA or ABBV?
AbbVie, Inc. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of 10.92%. Coya Therapeutics, Inc.'s return on equity of -57.41% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital COYACoya Therapeutics, Inc.99.81% -$0.13 $27.3M ABBVAbbVie, Inc.84.02% $1.02 $66.1B -
What do Analysts Say About COYA or ABBV?
Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 231.37%. On the other hand AbbVie, Inc. has an analysts' consensus of $246.63 which suggests that it could grow by 7.83%. Given that Coya Therapeutics, Inc. has higher upside potential than AbbVie, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COYACoya Therapeutics, Inc.7 0 0 ABBVAbbVie, Inc.13 9 0 -
Is COYA or ABBV More Risky?
Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.985%.
-
Which is a Better Dividend Stock COYA or ABBV?
Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.91% to investors and pays a quarterly dividend of $1.73 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 279% of its earnings as a dividend.
-
Which has Better Financial Ratios COYA or ABBV?
Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are smaller than AbbVie, Inc. quarterly revenues of $16.6B. Coya Therapeutics, Inc.'s net income of -$2.1M is lower than AbbVie, Inc.'s net income of $1.8B. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while AbbVie, Inc.'s PE ratio is 96.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 20.34x versus 6.63x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COYACoya Therapeutics, Inc.20.34x -- $3.6M -$2.1M ABBVAbbVie, Inc.6.63x 96.62x $16.6B $1.8B
-
Which has Higher Returns COYA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of 25.76%. Coya Therapeutics, Inc.'s return on equity of -57.41% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital COYACoya Therapeutics, Inc.99.81% -$0.13 $27.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About COYA or ACAD?
Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 231.37%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 34.53%. Given that Coya Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COYACoya Therapeutics, Inc.7 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is COYA or ACAD More Risky?
Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock COYA or ACAD?
Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COYA or ACAD?
Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Coya Therapeutics, Inc.'s net income of -$2.1M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 20.34x versus 3.73x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COYACoya Therapeutics, Inc.20.34x -- $3.6M -$2.1M ACADACADIA Pharmaceuticals, Inc.3.73x 14.93x $278.6M $71.8M
-
Which has Higher Returns COYA or AVIR?
Atea Pharmaceuticals, Inc. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of --. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Atea Pharmaceuticals, Inc.'s return on equity of -36.97%.
Company Gross Margin Earnings Per Share Invested Capital COYACoya Therapeutics, Inc.99.81% -$0.13 $27.3M AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M -
What do Analysts Say About COYA or AVIR?
Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 231.37%. On the other hand Atea Pharmaceuticals, Inc. has an analysts' consensus of $7.67 which suggests that it could grow by 66.67%. Given that Coya Therapeutics, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than Atea Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COYACoya Therapeutics, Inc.7 0 0 AVIRAtea Pharmaceuticals, Inc.2 1 0 -
Is COYA or AVIR More Risky?
Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Atea Pharmaceuticals, Inc. has a beta of 0.239, suggesting its less volatile than the S&P 500 by 76.143%.
-
Which is a Better Dividend Stock COYA or AVIR?
Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atea Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Atea Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COYA or AVIR?
Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are larger than Atea Pharmaceuticals, Inc. quarterly revenues of --. Coya Therapeutics, Inc.'s net income of -$2.1M is higher than Atea Pharmaceuticals, Inc.'s net income of -$42M. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Atea Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 20.34x versus 0.84x for Atea Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COYACoya Therapeutics, Inc.20.34x -- $3.6M -$2.1M AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M
-
Which has Higher Returns COYA or ELMD?
Electromed, Inc. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of 14.61%. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Electromed, Inc.'s return on equity of 20.35%.
Company Gross Margin Earnings Per Share Invested Capital COYACoya Therapeutics, Inc.99.81% -$0.13 $27.3M ELMDElectromed, Inc.78.42% $0.32 $45.4M -
What do Analysts Say About COYA or ELMD?
Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 231.37%. On the other hand Electromed, Inc. has an analysts' consensus of $36.67 which suggests that it could grow by 49.13%. Given that Coya Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COYACoya Therapeutics, Inc.7 0 0 ELMDElectromed, Inc.3 0 0 -
Is COYA or ELMD More Risky?
Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.264, suggesting its less volatile than the S&P 500 by 73.581%.
-
Which is a Better Dividend Stock COYA or ELMD?
Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COYA or ELMD?
Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are smaller than Electromed, Inc. quarterly revenues of $18.9M. Coya Therapeutics, Inc.'s net income of -$2.1M is lower than Electromed, Inc.'s net income of $2.8M. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 24.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 20.34x versus 3.16x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COYACoya Therapeutics, Inc.20.34x -- $3.6M -$2.1M ELMDElectromed, Inc.3.16x 24.15x $18.9M $2.8M
-
Which has Higher Returns COYA or LLY?
Eli Lilly & Co. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of 34.4%. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital COYACoya Therapeutics, Inc.99.81% -$0.13 $27.3M LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About COYA or LLY?
Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 231.37%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,202.37 which suggests that it could grow by 17.82%. Given that Coya Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Coya Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings COYACoya Therapeutics, Inc.7 0 0 LLYEli Lilly & Co.18 6 0 -
Is COYA or LLY More Risky?
Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock COYA or LLY?
Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios COYA or LLY?
Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Coya Therapeutics, Inc.'s net income of -$2.1M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 45.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 20.34x versus 14.26x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COYACoya Therapeutics, Inc.20.34x -- $3.6M -$2.1M LLYEli Lilly & Co.14.26x 45.18x $19.3B $6.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.61% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is down 7.32% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 2.38% over the past day.
